Abstract: Provided are novel Substituted Thiophene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R7 are as defined herein, as well as compositions comprising at least one Substituted Thiophene Derivative, and methods of using the Substituted Thiophene Derivatives for treating or preventing cancer in a patient.

Abstract: A user equipment (UE) and a method for sidelink failure management are provided. The method includes determining that a sidelink failure event associated with a paired sidelink destination UE has occurred and transmitting, to a first cell, a sidelink failure report indicating the sidelink failure event.

Abstract: A method for a UE to perform a MUSIM operation is provided. The method includes connecting to a first network associated with a first USIM; transmitting a request message to the first network, the request message including assistance information to request a time gap for the MUSIM operation; receiving a first time gap configuration from the first network in a case that a type of the time gap requested by the UE is aperiodic, the first time gap configuration indicating a starting SFN and a starting subframe of a first configured time gap; and in a case that the UE receives the first time gap configuration, switching to a second network, while keeping a connection to the first network, during the first configured time gap according to the first time gap configuration, the second network being associated with a second USIM.

Abstract: A device may be configured to signal sequence parameter information according to one or more of the techniques described herein. The sequence parameter set information may include in its second byte a syntax element specifying a chroma sampling relative to a luma sampling and a syntax element specifies a luma coding tree block size of each coding tree unit.

Abstract: A light-emitting device includes a first sub-pixel provided with a first light emitter, and a second sub-pixel provided with a second light emitter and constituting, together with the first sub-pixel, one of a plurality of pixels. The first light emitter has a first cathode, a first anode, and a first light-emitting layer containing a first quantum dot and disposed between the first cathode and the first anode. The second light emitter has a second cathode, a second anode, and a second light-emitting layer containing a second quantum dot and disposed between the second cathode and the second anode. The second quantum dot emits light having a longer light-emission wavelength than the first quantum dot. The first light-emitting layer is thicker than the second light-emitting layer.

Abstract: A method for a user equipment (UE) to perform small data transmission (SDT) is provided. The method includes receiving, from a base station (BS), system information that includes an SDT configuration, the SDT configuration including an SDT-specific timer; initiating an SDT procedure when the UE is in a radio resource control (RRC) inactive (RRC_INACTIVE) state; triggering a Buffer Status Report (BSR) during the SDT procedure; and starting or restarting the SDT-specific timer in response to triggering the BSR.

Abstract: A user equipment (UE) is described. The UE includes transmitting circuitry configured to transmit a demodulation reference signal (DMRS) for a physical uplink shared channel (PUSCH). In a case that a number of bits for downlink control information (DCI) used for indicating an index of an uplink antenna port(s) is more than 1 bit, the DMRS for the PUSCH is transmitted using the index of an uplink antenna port(s) indicated by using the DCI used for indicating the index of the uplink antenna port(s). In a case that a number of bits for downlink control information (DCI) used for indicating an index of an uplink antenna port(s) is 0 bit, the DMRS for the PUSCH is transmitted using an index of the uplink antenna port(s) configured by using first information.

Abstract: The present disclosure provides novel anhydrate crystalline Forms 1 and 4 of 4?-Ethynyl-2-fluoro-2?-deoxyadenosine and pharmaceutical compositions thereof, each of which may be useful for the inhibition of HIV reverse transcriptase, the treatment or prophylaxis of HIV infection and/or the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC.

Abstract: A display device (2) includes: a planarization film; and a light-emitting-element layer including an anode, an edge cover, an EL active layer, and a cathode in this sequence. The display device further includes: a first photospacer and a second photospacer each having a surface thereof covered by the cathode; and a lightning rod photospacer (44) including a second projection portion (44b) that is a part of the planarization film and having a surface thereof covered by a first metal film (44c) made of the same material and in the same layer as the anode.

Abstract: A method and apparatus for determining a BFD RS are provided. The method includes receiving at least one MAC CE for TCI state activation, each MAC CE indicating a CORESET and at least one TCI state, at least a subset of the indicated TCI state(s) belonging to a first group of TCI states associated with a first TRP; and performing first operations after determining that a total number of TCI states included in the first group of TCI states is larger than a first threshold number, the first operations including: selecting at least one first TCI state from the first group of TCI states; and determining at least one first BFD RS for detecting a first beam failure condition of the first TRP based on the at least one first TCI state.

Abstract: A display device includes: at least one first pixel including a first drive transistor and a first initialization transistor configured to initialize the first drive transistor; at least one second pixel including a second drive transistor and a second initialization transistor configured to initialize the second drive transistor; a first initialization line connected to the first drive transistor via the first initialization transistor; a second initialization line connected to the second drive transistor via the second initialization transistor; and a first temperature detection transistor connected to the second initialization line, the first temperature detection transistor including a gate connected to the first initialization line.

Abstract: This disclosure relates to video coding and more particularly to techniques for applying deblocking filters for coded video. In one example, a method of decoding chroma component parameter information for decoding video data comprises: receiving a picture parameter set (PPS) including syntax elements corresponding to a picture; parsing a flag in the PPS indicating whether chroma quantization parameter syntax elements are included in the PPS and whether chroma deblocking parameter syntax elements are included in the PPS; conditionally parsing the chroma quantization parameter syntax elements in the PPS based on the value of the flag; conditionally parsing the chroma deblocking parameter syntax elements in the PPS based on the value of the flag; deriving a quantization parameter based on the chroma quantization parameter syntax elements; and performing a deblocking filter based on the chroma deblocking parameter syntax elements.

Abstract: A method of decoding video data includes receiving a first decoding unit information message corresponding to a first decoding unit of a current access unit, determining a syntax element used to compute a decoded picture buffer output time of the current access unit is not present in the first decoding unit information message, and based on the syntax element not being present in the first decoding unit information message, inferring the value of the syntax element to be equal to a value of a corresponding instance of the syntax element in a second decoding unit information message, wherein the second decoding unit information corresponds to a second decoding unit belonging to the current access unit.

Abstract: Monovalent IL-12 heterodimeric Fc proteins that display attenuated potency at the IL-12 receptor compared to wild-type IL-12 and have an extended half-life compared to wild-type IL-12 are described. The monovalent heterodimeric IL-12 heterodimeric Fc proteins comprise a heterodimer comprising an IL-12p35 subunit first Fc domain fusion protein and an IL-p40 subunit second Fc domain fusion protein IL-12 and Fc domains wherein the first and second Fc domains comprise modifications that facilitate heterodimerization of the first Fc domain to the second Fc domain.

Abstract: Provided are novel Pyrazolopyrimidine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are as defined herein. Also provided are compositions comprising at least one Pyrazolopyrimidine Derivative, and methods of using the Pyrazolopyrimidine Derivatives for treating or preventing a herpesvirus infection in a patient.

Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

Abstract: A method and a user equipment for HARQ process ID selection are provided. The method includes: receiving a configuration message to configure a Configured Grant (CG) configuration and a set of HARQ process IDs that is available for the CG configuration, the set of HARQ process IDs including a first HARQ process ID for retransmission and a second HARQ process ID for initial transmission; determining that a CG physical uplink shared channel (PUSCH) corresponding to the CG configuration becomes available for transmission; selecting, based on a first HARQ process ID selection procedure, the first HARQ process ID or the second HARQ process ID from the set of HARQ process IDs for the CG PUSCH; and transmitting, based on the selected first or second HARQ process ID, a first Medium Access Control (MAC) Protocol Data Unit (PDU) for retransmission or a second MAC PDU for initial transmission on the CG PUSCH.

Abstract: The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Abstract: A method for a user equipment (UE) for performing a hybrid automatic repeat request (HARQ) codebook generation operation for downlink transmission(s) is disclosed. The method comprises receiving, from a base station, a dynamic scheduling configuration for HARQ feedback operation; receiving, from the base station, a scheduling signaling for a first physical downlink shared channel (PDSCH) reception with a first HARQ state feedback for the first PDSCH reception being disabled; and generating, for the HARQ feedback operation, a HARQ codebook excluding a first HARQ state for the first PDSCH reception.

Abstract: In a manufacturing method of a photoelectric conversion panel, a contact hole CH3 that exposes a part of an upper face of a photodiode and a contact hole CH2 that exposes a source connection electrode are formed in a first flattening film and in inorganic insulating films 105a to 105c, an inorganic insulating film 107 is formed, contact holes CH2a and CH3a are formed in the contact holes CH2 and CH3, respectively, and a bias line and a data line are formed in the contact holes CH2a and CH3a, respectively.